Cargando…
Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective
BACKGROUND: Worldwide, 1.7 million children younger than 15 years were living with HIV in 2021. Only 52% of them had access to antiretrovirals (ARVs). Lack of age-appropriate ARV formulations (i.e. easy to swallow for young infants, acceptable taste) remains the main obstacle to the access to ARVs....
Autores principales: | Rotsaert, Anke, Ogara, Collin, Mwanga-Amumpaire, Juliet, Kekitiinwa, Adeodata R., Musiime, Victor, Najjingo, Elizabeth, Kisitu, Grace P., Nazzinda, Rashidah, Nambi, Esther, Lee, Janice, Diallo, Mariama, Kyomuhendo, Flavia, Waweru, Moses, Andrieux-Meyer, Isabelle, Nöstlinger, Christiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031622/ https://www.ncbi.nlm.nih.gov/pubmed/36968554 http://dx.doi.org/10.1177/20499361231159993 |
Ejemplares similares
-
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study
por: Bekker, Adrie, et al.
Publicado: (2022) -
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020) -
Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010) -
Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010) -
Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)